Longitudinal tracking of circulating rare events in the liquid biopsy of stage III–IV non-small cell lung cancer patients

• Published in: Discover. Oncology 2024-05, Vol.15 (1), p.142-142, Article 142
• Main Authors: Bai, Lily, Courcoubetis, George, Mason, Jeremy, Hicks, James B., Nieva, Jorge, Kuhn, Peter, Shishido, Stephanie N.
• Format: Article
• Language: English
• Subjects: Automation; Biopsy; Cancer Research; Cells; Cloning; Decision making; Enrollments; FDA approval; Internal Medicine; Longitudinal studies; Lung cancer; Mann-Whitney U test; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Molecular Medicine; Oncology; Patients; Prostate cancer; Radiotherapy; Surgical Oncology; Survival analysis
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-024-00984-4

In the United States, lung cancer is the second most common type of cancer with non-small cell lung cancer (NSCLC) encompassing around 85% of total lung cancer cases. Late-stage patients with metastatic disease have worsening prognosis, highlighting the importance of longitudinal disease monitoring. Liquid biopsy (LBx) represents a way for physicians to non-invasively track tumor analytes, such as circulating tumor cells (CTCs), and understand tumor progression in real-time through analyzing longitudinal blood samples. CTCs have been shown to be effective predictive biomarkers in measuring treatment efficacy and survival outcomes. We used the third-generation High-Definition Single Cell Assay (HDSCA3.0) workflow to analyze circulating rare events longitudinally during treatment in a cohort of 10 late-stage NSCLC patients, identifying rare events including circulating cancer cells (i.e., CTCs), and oncosomes. Here, we show (1) that there is a cancer specific LBx profile, (2) there is considerable heterogeneity of rare cells and oncosomes, and (3) that LBx data elements correlated with patient survival outcomes. Additional studies are warranted to understand the biological significance of the rare events detected, and the clinical potential of the LBx to monitor and predict response to treatment in NSCLC patient care.